DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Effects of Home-Based Emotional Disclosure in Rheumatoid Arthritis

Information source: UMC Utrecht
Information obtained from ClinicalTrials.gov on December 31, 2007
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rheumatoid Arthritis

Intervention: home-based emotional disclosure (Behavioral); time management control condition (Behavioral)

Phase: Phase 2

Status: Completed

Sponsored by: UMC Utrecht

Official(s) and/or principal investigator(s):
Henriët van Middendorp, PhD, Principal Investigator, Affiliation: Utrecht University, Department of Clinical and Health Psychology
Rinie Geenen, PhD, Study Chair, Affiliation: Utrecht University, Department of Clinical and Health Psychology
Johannes WJ Bijlsma, PhD, MD, Study Director, Affiliation: University Medical Center Utrecht, Department of Rheumatology & Clinical Immunology

Summary

The purpose of the study is threefold: 1) to develop a home-based emotional disclosure intervention inducing core elements of change (emotional engagement, cognitive restructuring, and positive future directedness); 2) to examine in a randomized controlled trial in patients with rheumatoid arthritis the induction of the core elements and the feasibility of the intervention for home application; and, 3) to examine the psychological, clinical, and physiological effects of the adapted emotional disclosure intervention and the modulating role of cognitive-emotional change and individual differences in emotion regulation.

Clinical Details

Official title: Psychological, Physiological, and Clinical Consequences of Emotional Disclosure in Rheumatoid Arthritis (RA)

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Primary outcome:

Depressed mood.

Cheerful mood.

Both measures at baseline, 1 week after intervention, and 3 months after intervention.

Secondary outcome:

Feasibility: adherence, compliance with instructions, perceived viability, clinical safety; all measured during or immediately after the intervention).

Induction of core elements: immediate negative affect change, emotion, insight, and optimism word use during the intervention.

Clinical measures: Joint score; Erythrocyte Sedimentation Rate; both measures at baseline, 1 week after intervention, and 3 months after intervention.

Physiological measures: 24-h Urinary cortisol; 24-h Urinary noradrenaline; IL-6; IFN-γ; IL-10; all measures at baseline, 1 week after intervention, and 3 months after intervention.

Detailed description: Emotional disclosure has been suggested to alleviate psychological and physical stress in chronically ill people. Emotional engagement, cognitive restructuring, and positive future directedness are considered core elements to induce change in emotional disclosure interventions. The aim of our randomized controlled trial in patients with rheumatoid arthritis is to examine the psychological, clinical, and physiological effects of an emotional disclosure intervention adapted for home application and the modulating role of cognitive-emotional change and individual differences in emotion regulation.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: Diagnosis of rheumatoid arthritis according to the criteria of the American College of Rheumatology (Arthritis Rheum 1988;31: 315-24 Written informed consent

Locations and Contacts

Utrecht University, Department of Clinical and Health Psychology, Utrecht PO Box 80.140, 3508 TC, Netherlands
Additional Information

Starting date: September 2002
Ending date: June 2003
Last updated: April 16, 2007

Page last updated: December 31, 2007

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008